Dr. Campbell Murray
is a Managing Director of the Novartis Venture Funds
in Cambridge, MA, USA.
Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the director of special projects reporting to the president & CEO. Campbell, is a New Zealand trained physician, Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves as a director on the boards of Aileron Therapeutics, Akebia Therapeutics, Alios BioPharma, BioRelix, ProCertus BioPharm and Tokai Pharmaceuticals and as an observer on the board of MicroCHIPS and Tepha.
Portfolio Companies
Aileron Therapeutics Inc. (Board Seat)
Akebia Therapeutics, Inc. (Board Seat)
Alios BioPharma, Inc. (Board Seat)
BioRelix Inc. (Board Seat)
ProCertus BioPharm Inc. (Board Seat)
Tokai Pharmaceuticals (Board Seat)
MicroCHIPS Inc.
Omeros Corporation
Tepha Inc.
ZymeQuest
Back
